



## **Idera to Release 2016 First Quarter Results on May 9, 2016**

May 5, 2016 11:31 AM EDT

CAMBRIDGE, Mass. and EXTON, Pa., May 05, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today announced that first quarter results for 2016 are expected to be released on Monday, May 9, 2016 after the close of the U.S. Financial Markets.

The company will host a conference call and live audio webcast at 5:00 P.M. Eastern Time on the same day. During the conference call, Idera management will discuss the company's recent progress and provide a clinical update from the ongoing Phase 1/2 trial of IMO-8400 in Waldenstrom's Macroglobulinemia.

Live audio webcast of Idera's presentations will be accessible in the Investors section of Idera's website at <http://www.iderapharma.com>. To participate in the conference call, please dial (844) 882-7837 (domestic) and (574) 990-9824 (international). Archived versions will also be available on the Company's website after the event for 90 days.

### **About Idera Pharmaceuticals**

Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases. Idera's proprietary technology involves using a TLR-targeting technology, to design synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. In addition to its TLR programs, Idera has created a third generation antisense technology platform using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit [www.iderapharma.com](http://www.iderapharma.com).

### Investor and Media Contact

Robert Doody

VP, IR & Corporate Communications

617-679-5515 (office)

484-639-7235 (mobile)

[rdoody@iderapharma.com](mailto:rdoody@iderapharma.com)



Idera Pharmaceuticals, Inc.